# Phase 1 Single Subcutaneous Dose Study of MLN1202

> **NCT02426021** · PHASE1 · WITHDRAWN · sponsor: **Takeda**

## Conditions studied

- Healthy Japanese and Caucasian Male Adults

## Interventions

- **DRUG:** MLN1202
- **DRUG:** MLN1202 Placebo

## Key facts

- **NCT ID:** NCT02426021
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-04
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business decision; No Safety or Efficacy Concerns
- **Last updated:** 2016-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02426021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02426021, "Phase 1 Single Subcutaneous Dose Study of MLN1202". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02426021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*